Clinical trials: End of Life
Perinatal Death, Neonatal Death
Verbal Autopsy of Maternal Deaths, Stillbirths, and Neonatal Deaths in BetterBirth
The purpose of this study is to conduct Verbal Autopsies of deaths ( stillbirths and neonatal deaths together) identified in the BetterBirth trial to identify their potential causes, timing, and social determinants.
- Conditions
- Perinatal Death, Neonatal Death, Stillbirth
- Trial name
- NCT03213509
- Testing
- Interview (Social and Verbal Autopsy)
- Where
- India
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Harvard School of Public Health (HSPH)
Advanced Solid Tumors
Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)
The purpose of this study is to evaluate safety and tolerability, pharmacokinetics (PK), and preliminary antitumor activity of intratumoral (IT) / intralesional injections of MK-4621 delivered via the JetPEI™ in vivo linear…
- Trial name
- NCT03739138
- Testing
- MK-4621, Pembrolizumab
- Where
- 9 sites in France, Germany and 2 more
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Kidney Failure
Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates
Some patients who need kidney transplants have high levels of antibodies that make them incompatible with most potential deceased donor kidney offers.
- Trial name
- NCT00986947
- Testing
- IVIg and rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Heart Transplant
Donors After Circulatory Death Heart Trial
To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
- Trial name
- NCT03831048
- Testing
- OCS Heart System, Cold Storage
- Where
- 25 sites in United States
- Volunteers
- 180 people
- Sponsor
- TransMedics
Non-small Cell Lung Cancer
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
The purpose of the study is to evaluate the efficacy and safety of bintrafusp alfa (M7824) compared with pembrolizumab in participants with advanced NSCLC with high PD-L1-tumor expression, with no epidermal growth factor receptor…
- Trial name
- NCT03631706
- Testing
- M7824, Pembrolizumab
- Where
- 119 sites in United States, Argentina and 16 more
- Volunteers
- 304 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Renal Failure
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
- Trial name
- NCT01976390
- Testing
- Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University
Advanced/Metastatic Gastroesophageal Adenocarcinoma
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared with chemotherapy alone in participants with advanced/metastatic…
- Trial name
- NCT04662710
- Testing
- Pembrolizumab, Lenvatinib, Oxaliplatin
- Where
- 177 sites in United States, Argentina and 22 more
- Volunteers
- 895 people
- Sponsor
- Merck Sharp & Dohme LLC
Death, Sudden, Cardiac, Out-Of-Hospital Cardiac Arrest
Pre-hospital ECMO in Advanced Resuscitation in Patients With Refractory Cardiac Arrest. ( SUB30 )
To establish whether a pre-hospital advanced physician/ paramedic cardiac arrest team that is ECMO capable can establish ECMO flow within 30 minutes of collapse.
- Conditions
- Death, Sudden, Cardiac, Out-Of-Hospital Cardiac Arrest, Ventricular Fibrillation, Cardiopulmonary Arrest With Successful Resuscitation
- Trial name
- SUB30 (NCT03700125)
- Testing
- ECMO resuscitation
- Where
- 2 sites in United Kingdom
- Volunteers
- 5 people
- Sponsor
- Barts & The London NHS Trust
COVID-19
Ramipril for the Treatment of COVID-19
In this study we propose to treat 560 patients with ramipril or placebo for 14 days. After an initial evaluation for COVID-19 status, medical history, and symptom assessment, patients will receive either 2.5 mg/day of ramipril or…
- Trial name
- RAMIC (NCT04366050)
- Testing
- Ramipril 2.5 MG Oral Capsule
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of California, San Diego
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
Metastatic Triple Negative Breast Cancer
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
In this study, participants with metastatic triple negative breast cancer (mTNBC) will be randomly assigned to receive either single agent pembrolizumab or single agent chemotherapy chosen by the treating physician (Treatment of…
- Trial name
- NCT02555657
- Testing
- pembrolizumab, capecitabine, eribulin
- Volunteers
- 622 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer NSCLC
A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients
This is a single-arm phase II clinical trial evaluating the safety and efficacy of the PD-L1 inhibitor durvalumab as first-line therapy in 47 patients with advanced NSCLC and ECOG Performance Status 2 (PS2).
- Trial name
- NCT02879617
- Testing
- durvalumab
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
UC (Urothelial Cancer)
Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab + epacadostat vs pembrolizumab + placebo as a treatment for recurrent or progressive metastatic urothelial carcinoma in patients who have failed a…
- Trial name
- NCT03374488
- Testing
- Pembrolizumab, Epacadostat
- Where
- 135 sites in United States, Australia and 16 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
Metastatic Non Small Cell Lung Cancer
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)
The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline placebo plus docetaxel.
- Trial name
- NCT04725188
- Testing
- Pembrolizumab/Vibostolimab coformulation, Docetaxel
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 255 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronary Artery Disease, Left Ventricular Dysfunction
DEfibrillators To REduce Risk by MagnetIc ResoNance Imaging Evaluation
This trial is a prospective, multi-center, randomized study of patients with coronary artery disease (CAD) and mild to moderate left ventricular (LV) dysfunction.
- Conditions
- Coronary Artery Disease, Left Ventricular Dysfunction, Sudden Cardiac Death
- Trial name
- DETERMINE (NCT00487279)
- Testing
- Defibrillator, Control
- Where
- 56 sites in United States
- Volunteers
- 81 people
- Sponsor
- Abbott Medical Devices
Anesthetic Ventilatory Requirements
Rebreathing of Carbon Dioxide With a Device Used for Giving Inhalational Anaesthesia
The anesthesia gas reflector (AnaConDa) is built on the adsorptive capacity of active carbon which also adsorbs carbon dioxide in exhaled air.
- Trial name
- NCT01339013
- Testing
- Anesthetic Conserving Device (AnaConDa )
- Where
- Sweden
- Volunteers
- 6 people
- Sponsor
- Region Skane
Chronic Obstructive Pulmonary Disease
Reliability, Sensitivity and Validity of the 6 Minute Step Test in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease (COPD) leads to a reduction in exercise capacity that affects the quality of life and increases mortality of these patients.
- Trial name
- NCT01298661
- Testing
- Six-minute Step Test
- Where
- Brazil
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Universidade Federal de Sao Carlos
Bladder Cancer
MK-3475/BCG in High Risk Superficial Bladder Cancer
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet…
- Trial name
- MARC (NCT02324582)
- Testing
- Intravenous MK-3475/ Intravesical BCG
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Southern Illinois University
Epilepsy, Sudden Cardiac Death
Optimization of VNS in Epileptic Patients to Induce Cardioprotection
This study is a non-randomized, prospective study in patients with a diagnosis of epilepsy and previously implanted FDA approved Vagus Nerve Stimulation (VNS) devices.
- Trial name
- NCT04387435
- Testing
- A change or titration in the current or frequency settings of the VNS therapy system.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Los Angeles
Brain Death, Heart Failure
Intravenous Thyroxine for Heart-Eligible Organ Donors
This randomized controlled trial will evaluate whether intravenous thyroxine infusion given to brain-dead organ donors who are eligible to donate hearts for 12 hours will result in more hearts transplanted than saline placebo
- Trial name
- NCT04415658
- Testing
- Thyroxine, Saline
- Where
- 14 sites in United States
- Volunteers
- 838 people
- Sponsor
- Washington University School of Medicine